Feds Want ‘Pharma Bro’ Martin Shkreli Held in Contempt
Authorities say Shkreli hasn’t paid a $64.6 million judgment and may be violating a court order barring him from the pharmaceutical business.
Drew Angerer/Getty Images
Martin Shkreli, the so-called “pharma bro” known for jacking up the price of a life-saving drug called Daraprim, has apparently not learned his lesson. The Federal Trade Commission and a host of state plaintiffs are calling for the 39-year-old to be held in contempt, saying he hasn’t handed over documents or sat for an interview to prove whether he ignored a court order barring him from the pharmaceutical industry. In a court filing on Friday, the plaintiffs also said there are “concerns” about Shkreli’s nonpayment of a $64.6 million judgment. As The Daily Beast reported last summer, in July Shkreli launched a new business called Druglike, a “drug discovery software platform,” though the startup billed itself as a “blockchain/Web3 software company and not a pharmaceutical company.” Reached for comment, Shkreli said, “I don’t talk to reporters. Y’all police.”
See more of our coverage in your search results.
Got a tip? Send it to The Daily Beast here.
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.